Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

Trial ID or NCT#

NCT00855647

Status

not recruiting iconNOT RECRUITING

Purpose

To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.

Official Title

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Eligible patients will have clinical stage T1c through T2b, initial PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved. - Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed. - Adult men will be considered. - No life expectancy restrictions will apply. - Performance Status will not be considered. - No requirements for organ or marrow function will be made - Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
  1. - No prior prostate treatment will be allowed. - The use of other concurrent Investigational Agents will not be allowed. - No exclusion requirements due to co-morbid disease or incurrent illness. - No requirements regarding history of allergic reactions. - Pregnancy or nursing patients is not applicable (ie. patients are male).

Investigator(s)

James D. Brooks
James D. Brooks
Surgical oncologist, Urologic surgeon
Keith and Jan Hurlbut Professor
Harcharan Gill
Harcharan Gill
Urologic oncologist, Urologist, Genitourinary specialist, Urologic surgeon
Kathryn Simmons Stamey Professor, Emeritus

Contact us to find out if this trial is right for you.

Contact

Gillian McFarlane
6507212034